AMRN vs ORGO

AMRN's Piotroski F-Score of 2/9 indicates severe financial distress, with weak profitability, declining revenue, and negative earnings trends. The absence of an Altman Z-Score raises concern about potential bankruptcy risk, especially given the company's negative ROE, ROA, and persistent losses despite a strong gross margin. While the company exhibits a low debt-to-equity ratio and high liquidity, these strengths are overshadowed by a 21% YoY revenue decline and a 94.7% Q/Q EPS drop. Analysts have issued a 'underperform' rating with a target price below current levels, reflecting skepticism about near-term sustainability. The stock's recent 87% 1-year gain is likely driven by speculative momentum rather than fundamentals.

ORGO presents a stark contradiction between explosive growth and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 2/9. While the company shows massive YoY revenue (78.1%) and earnings growth (555.2%) and trades below both its Graham Number ($2.92) and Intrinsic Value ($4.72), the technical trend is severely bearish (0/100). The strong liquidity ratios and low debt/equity are offset by the poor F-Score and a 1-year price decline of nearly 40%. Consequently, the stock is a high-risk value play where growth potential is currently overshadowed by fundamental instability.